News Astellas Pharma Inc.

Equities

4503

JP3942400007

Delayed Japan Exchange Other stock markets 02:00:00 2024-04-16 am EDT			5-day change	1st Jan Change
1,452 ^JPY	+0.38%		-9.05%	-13.91%

01:39pm	Middle East Tensions Blunt Asian Stock Markets Excepting China	MT
09:01am	Astellas Pharma Cuts Attributable Profit Forecast for Fiscal Year Ended March	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Middle East Tensions Blunt Asian Stock Markets Excepting China	07:39am	MT
Astellas Pharma Cuts Attributable Profit Forecast for Fiscal Year Ended March	03:01am	MT
Japan's Nikkei sags as Iran attack, Wall Street sell-off sour sentiment	02:33am	RE
Japan's Nikkei drops 1% as Iran attack, Wall Street sell-off fuel risk aversion	10:38pm	RE
Astellas Pharma Inc. Provides Impairment Loss for Intangible Assets Guidance for the Fourth Quarter 2023	Apr. 12	CI
Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024	Apr. 12	CI
U.S. FDA Accepts Astellas' Supplemental New Drug Application for IZERVAY (avacincaptad pegol intravitreal solution) for Geographic Atrophy	Apr. 04	AQ
Jefferies Adjusts Astellas Pharma’s Price Target to 2,100 Yen From 2,200 Yen, Keeps at Buy	Apr. 03	MT
U.S. FDA Accepts Astellas? Supplemental New Drug Application for Izervay (Avacincaptad Pegol Intravitreal Solution) for Geographic Atrophy	Mar. 31	CI
Pfizer, Astellas' Combination Therapy Application For Bladder Cancer Accepted in China	Mar. 28	MT
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer	Mar. 28	CI
Final dividend	Mar. 27	FA
Astellas VYLOY Approved in Japan for Treatment of Gastric Cancer	Mar. 27	AQ
Iveric Bio - Astellas Receives Permanent J-code for IZERVAY for Geographic Atrophy	Mar. 27	AQ
Astellas Pharma Inc.'s Vyloy?? (zolbetuximab) Approves in Japan for Treatment of Gastric Cancer	Mar. 26	CI
Astellas Receives Positive CHMP Opinion for XTANDI in Additional Recurrent Early Prostate Cancer Treatment Setting	Mar. 25	AQ
Astellas Pharma Inc. Receives Positive CHMP Opinion for XTANDI? in Additional Recurrent Early Prostate Cancer Treatment Setting	Mar. 22	CI
Bayer to seek approval for menopausal relief drug after third trial win	Mar. 19	RE
CytomX Therapeutics, Inc. Announces Milestone Achievement in Prospective T-Cell Engaging Bispecific Collaboration with Astellas	Mar. 18	CI
Hewlett Packard Enterprise's HPE Asset Upcycling Services Selected by Astellas Pharma	Mar. 14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Astellas Pharma Inc.

Equities

4503

JP3942400007

Summary

Filters